Dutasteride CAS 164656-23-9: A Pharmaceutical Breakthrough for Benign Prostatic Hyperplasia (BPH)
Benign Prostatic Hyperplasia (BPH) affects a significant portion of aging men, and NINGBO INNO PHARMCHEM CO.,LTD. is proud to supply Dutasteride CAS 164656-23-9, a crucial pharmaceutical compound for its management. Dutasteride is a potent dual inhibitor of type 1 and type 2 5α-reductase, enzymes responsible for converting testosterone into dihydrotestosterone (DHT). Elevated DHT levels are closely linked to the progression of BPH. By significantly reducing these levels, Dutasteride for BPH treatment offers a more effective and consistent therapeutic approach compared to single-isoenzyme inhibitors. The ability of Dutasteride to achieve a greater and more sustained reduction in plasma DHT makes it a valuable asset in alleviating the symptoms associated with an enlarged prostate.
The mechanism of action of this 5α-reductase inhibitor Dutasteride is central to its efficacy in BPH. The stable enzyme-NADP adduct complexes formed inhibit the conversion to DHT more comprehensively. This dual inhibition not only lowers circulating DHT but also demonstrates distinct advantages in treating BPH and other DHT-dependent conditions. Sourcing high purity Dutasteride supplier is vital for ensuring the efficacy and safety of treatments. NINGBO INNO PHARMCHEM CO.,LTD. prioritizes quality, ensuring that the Dutasteride provided meets the highest pharmaceutical standards. This commitment allows healthcare providers to confidently prescribe treatments incorporating this active pharmaceutical ingredient.
For healthcare professionals and patients seeking advanced BPH management solutions, understanding the benefits of Dutasteride is key. The competitive price of Dutasteride, when considering its superior efficacy and advanced formulation, makes it an attractive option. NINGBO INNO PHARMCHEM CO.,LTD. provides a reliable source for purchasing Dutasteride, ensuring a consistent supply for treatment needs. The pharmaceutical expertise of our company underscores our dedication to improving patient outcomes through the provision of high-quality, effective compounds like Dutasteride CAS 164656-23-9.
Perspectives & Insights
Quantum Pioneer 24
“By significantly reducing these levels, Dutasteride for BPH treatment offers a more effective and consistent therapeutic approach compared to single-isoenzyme inhibitors.”
Bio Explorer X
“The ability of Dutasteride to achieve a greater and more sustained reduction in plasma DHT makes it a valuable asset in alleviating the symptoms associated with an enlarged prostate.”
Nano Catalyst AI
“The mechanism of action of this 5α-reductase inhibitor Dutasteride is central to its efficacy in BPH.”